JPH0529008B2 - - Google Patents

Info

Publication number
JPH0529008B2
JPH0529008B2 JP60102165A JP10216585A JPH0529008B2 JP H0529008 B2 JPH0529008 B2 JP H0529008B2 JP 60102165 A JP60102165 A JP 60102165A JP 10216585 A JP10216585 A JP 10216585A JP H0529008 B2 JPH0529008 B2 JP H0529008B2
Authority
JP
Japan
Prior art keywords
weight
urea
external preparation
oil
hydrogenated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60102165A
Other languages
Japanese (ja)
Other versions
JPS61260016A (en
Inventor
Hiroshi Yamaguchi
Shigeo Tanaka
Ichiro Kawamata
Kenichi Suzuki
Susumu Nakamura
Yasuji Takashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP60102165A priority Critical patent/JPS61260016A/en
Publication of JPS61260016A publication Critical patent/JPS61260016A/en
Publication of JPH0529008B2 publication Critical patent/JPH0529008B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Description

【発明の詳細な説明】[Detailed description of the invention]

（産業上の利用分野） 本発明は外用製剤に関し、更に詳しくは皮膚角
化異常症の治療に用いる外用製剤に関する。 （従来の技術） 魚鱗癬、老人性乾皮症、アトピー皮膚、進行性
指掌角皮症（乾燥タイプの主婦湿疹）、足蹠部皹
裂性皮膚炎、掌蹠角化症、毛孔性苔癬などの皮膚
角化異常症の治療には尿素含有外用剤が有効であ
る。尿素は水溶性であるため、従来は尿素水溶液
を合成界面活性剤で油脂成分に分散した乳剤性軟
膏、クリーム、ローシヨンとして使用されてい
た。 （発明が解決しようとする問題点） しかしながら、これらの製剤中に含有されてい
る合成界面活性剤は、皮膚からの水分蒸散を促進
し、尿素含有外用剤の治療効果を著しく減少させ
てしまう。 （問題点を解決するための手段） 本発明者らは、従来の尿素含有外用剤の欠点を
解消すべく鋭意研究を重さねた結果、分散剤とし
て水素添加リン脂質を用いることにより皮膚角化
異常症に対する尿素含有外用剤の治療効果が著し
く増大することを見出し、本発明を完成した。 （問題点を解決するための手段） 本発明者らは、従来の尿素含有外用剤の欠点を
解消すべく鋭意研究を重さねた結果、分散剤とし
て水素添加リン脂質を用いることにより皮膚角化
異常症に対する尿素含有外用剤の治療効果を増大
するとともに長期保存による製剤の変質をおこさ
ないことを見出して本発明を完成した。 本発明の目的物は尿素、水素添加リン脂質、水
および油脂成分を含有してなる外用製剤である。 本発明において、尿素は全量の２〜30重量％、
好ましくは５〜20重量％を配合する。この範囲以
下の配合量では治療効果は期待し難く、この範囲
以上の配合量では皮膚に対する刺激が強すぎて実
用的ではない。 水素添加リン脂質は大豆リン脂質、卵黄リン脂
質などのリン脂質に水素添加したもの、好ましく
はヨウ素価が15以下のものを用い、全量の0.2〜
30重量％、好ましくは１〜20重量％を配合する。 水は精製水を用い、全量の５〜80重量％、好ま
しくはＯ／Ｗタイプの製剤では30〜80重量％、
Ｗ／Ｏタイプの製剤では５〜15重量％を配合す
る。 油脂成分は液状〜固体状の炭化水素（たとえ
ば、流動パラフイン、白色ワセリン、固形パラフ
イン、ミクロクリスタルワツクス、スクラワン、
スクワレンなど）、脂肪族高級アルコール（たと
えば、セチルアルコール、ヘキサデシルアルコー
ル、ステアリルアルコール、オレインアルコール
など）、高級脂肪酸と高級アルコールのエステル
（たとえば、ミツロウ、鯨ロウなど）、高級脂肪酸
と低級アルコールのエステル（たとえば、ミリス
チン酸イソプロピル、パルミチン酸イソプロピル
など）、植物油（たとえば、オリーブ油、アーモ
ンド油、落花生油など）、改質植物油（たとえば、
硬化ヒマシ油、中鎖脂肪酸グリセライドなど）、
脂肪酸とグリセリンのエステル（たとえば、グリ
セリンモノステアレート、グリセリンモノオレー
トなど）、脂肪酸とプロピレングリコールのエス
テル（たとえば、プロピレングリコールモノステ
アレート、プロピレングリコールモノオレートな
ど）、高級脂肪酸（たとえば、パルミチン酸、ス
テアリン酸など）を用い、Ｏ／Ｗタイプの製剤に
おいては全量の５〜60重量％、好ましくは10〜30
重量％、Ｗ／Ｏタイプの製剤においては全量の70
〜90重量％、好ましくは80〜88重量％を配合す
る。 この他必要に応じて、ゲル化剤〔製剤の保存安
定性を増大；全量の0.01〜２重量％、好ましくは
0.02〜0.5重量％を配合；たとえば、カルボキシ
メチルセルロース、カルボキシビニルポリマー
（ハイビスワコー：商品名、和光純薬(株)製）、ポリ
ビニルアルコールなど〕、湿潤剤（製剤の湿潤作
用を増大；全量の0.1〜20重量％、好ましくは0.5
〜10重量％を配合；たとえば、プロピレングリコ
ール、グリセリン、ソルビツトなど）、キレート
剤（製剤の保存安定性を増大；たとえば、エチレ
ンジアミンテトラ酢酸ジナトリウムなど）、防腐
剤（たとえば、パラオキシ安息香酸メチル、同エ
チル、同プロピル、同ブチル、デヒドロ酢酸およ
びその塩など）、PH調整剤（たとえば、クエン酸、
乳酸、酒石酸およびその塩並びにジイソプロパノ
ールアミンなど：調整すべきPHは製剤の安定性に
基づいて決定され、製剤は通常弱酸性ないし弱ア
ルカリ性に保たれるのが好ましい。）などを配合
することができる。 また必要があれば、抗生物質（たとえば、硫酸
ゲンタマイシン、硫酸フラジオマイシンなど）、
抗ヒスタミン剤（たとえば、ジフエンヒドラミ
ン、塩酸イソチペンジルなど）、殺菌剤（たとえ
ば、塩化デカリニウム、塩酸クロルヘキシジン、
グルコン酸クロルヘキシジン、スルフイソミジン
など）、抗炎症剤（たとえば、グリチルレチン酸、
インドメタシン、酢酸デキサメタゾン、フルオシ
ノロンアセトニド、吉草酸ベタメタゾン、酪酸プ
ロピオン酸ヒドロコルチゾンなど）、ビタミン酸
（たとえば、ビタミンＡ、ビタミンＤ、ビタミン
Ｅなど）などの薬効成分および香料（たとえば、
ラベンダー、ネロリー、ストロベリー、ヘリオト
ロープ、ローズ、アミルアセテートなど）を適宜
組み合わせて配合することができる。 さらにまた必要があれば、皮膚に対する刺激が
少ない非イオン界面活性剤（たとえば、脂肪酸モ
ノグリセライド類、ソルビタン脂肪酸エステル
類、ポリオキシエチレン高級脂肪酸エステル類な
ど）を尿素の効果を低下させない程度に少量配合
することができる。 本発明の外用製剤は、たとえば下記の方法によ
り製造することができる。 すなわち、加温した油脂成分に水素添加リン脂
質を溶解し、これに加温した尿素水溶液を加えて
撹拌しながら冷却するか、または全成分をすべて
混合し、加温撹拌後冷却する。 製造上特に注意すべき点はないが、加温時撹拌
の際にホモミキサーなどを用いてエマルジヨンの
粒子を微細化することにより保存安定性が大きい
外用製剤を得ることができる。 （作用） リン脂質を配合した製剤は、長期保存によつて
ときには変色するなどの不都合を生ずることがあ
る。 しかしながら、本発明の外用製剤は、分散剤と
して水素添加リン脂質、特にヨウ素価15以下の水
素添加リン脂質を用いることにより、抗酸化剤を
用いることがなくても保存中に製剤の変色をおこ
さず、分散剤として合成界面活性剤を用いた尿素
含有外用剤よりも皮膚角化異常症に対する治療効
果が著しく増大する。 以下、試験例を挙げて本発明の外用製剤の作用
を示す。 試験例 １ ヨウ素価の異なる大豆リン脂質または水素添加
大豆リン脂質にそれぞれ10重量％用いて、後記実
施例１に従つてクリーム状の各種試料を調製し
た。 この各種試料50ｇを内容量60ｇの透明ガラスビ
ンにいれ、40℃恒温室に保存してその経時変化を
調べた。 その結果を第１表に示す。 (Industrial Application Field) The present invention relates to an external preparation, and more particularly to an external preparation used for the treatment of skin dyskeratosis. (Conventional technology) Ichthyosis, senile xeroderma, atopic skin, progressive digital palmar keratoderma (dry type of housewife's eczema), footpad fissuring dermatitis, palmoplantar keratosis, lichen pilaris External preparations containing urea are effective for the treatment of skin dyskeratosis such as. Since urea is water-soluble, it has conventionally been used in emulsion ointments, creams, and lotions in which an aqueous urea solution is dispersed in oil and fat components using a synthetic surfactant. (Problems to be Solved by the Invention) However, the synthetic surfactants contained in these preparations promote water evaporation from the skin, significantly reducing the therapeutic effect of urea-containing external preparations. (Means for Solving the Problems) As a result of extensive research in order to eliminate the drawbacks of conventional urea-containing topical preparations, the present inventors have developed a solution to skin irritation by using hydrogenated phospholipids as a dispersant. The present invention has been completed based on the discovery that the therapeutic effect of a urea-containing external preparation for dyspepsia is significantly increased. (Means for Solving the Problems) As a result of extensive research in order to eliminate the drawbacks of conventional urea-containing topical preparations, the present inventors have developed a solution to skin irritation by using hydrogenated phospholipids as a dispersant. The present invention was completed based on the discovery that the therapeutic effect of a urea-containing external preparation for dyspepsia is increased and that the preparation does not deteriorate during long-term storage. The object of the present invention is an external preparation containing urea, hydrogenated phospholipids, water, and oil and fat components. In the present invention, urea is 2 to 30% by weight of the total amount,
Preferably, it is blended in an amount of 5 to 20% by weight. If the amount is less than this range, no therapeutic effect can be expected, and if the amount is more than this range, the irritation to the skin will be too strong to be practical. Hydrogenated phospholipids are hydrogenated phospholipids such as soybean phospholipids and egg yolk phospholipids, preferably those with an iodine value of 15 or less, and 0.2 to 0.2 of the total amount.
30% by weight, preferably 1 to 20% by weight. For water, use purified water, 5 to 80% by weight of the total amount, preferably 30 to 80% by weight for O/W type formulations,
In W/O type preparations, the amount is 5 to 15% by weight. The oil and fat components are liquid to solid hydrocarbons (e.g., liquid paraffin, white petrolatum, solid paraffin, microcrystal wax, squalane,
(e.g., squalene), aliphatic higher alcohols (e.g., cetyl alcohol, hexadecyl alcohol, stearyl alcohol, oleic alcohol, etc.), esters of higher fatty acids and higher alcohols (e.g., beeswax, spermaceti, etc.), esters of higher fatty acids and lower alcohols. (e.g., isopropyl myristate, isopropyl palmitate, etc.), vegetable oils (e.g., olive oil, almond oil, peanut oil, etc.), modified vegetable oils (e.g.,
hydrogenated castor oil, medium chain fatty acid glycerides, etc.)
Esters of fatty acids and glycerin (e.g., glycerin monostearate, glycerin monooleate, etc.), esters of fatty acids and propylene glycol (e.g., propylene glycol monostearate, propylene glycol monooleate, etc.), higher fatty acids (e.g., palmitic acid, stearin, etc.) acids, etc.), and in O/W type preparations, 5 to 60% by weight of the total amount, preferably 10 to 30% by weight of the total amount.
% by weight, 70% of the total amount in W/O type formulations
~90% by weight, preferably 80-88% by weight. In addition, if necessary, a gelling agent [increases the storage stability of the preparation; 0.01 to 2% by weight of the total amount, preferably
Contains 0.02 to 0.5% by weight; for example, carboxymethylcellulose, carboxyvinyl polymer (Hibis Wako: trade name, manufactured by Wako Pure Chemical Industries, Ltd.), polyvinyl alcohol, etc.), wetting agent (increases the wetting effect of the preparation; 0.1% of the total amount) ~20% by weight, preferably 0.5
~10% by weight; e.g., propylene glycol, glycerin, sorbitate, etc.), chelating agents (increases storage stability of the formulation; e.g., disodium ethylenediaminetetraacetate), preservatives (e.g., methyl paraoxybenzoate, ethyl, propyl, butyl, dehydroacetic acid and its salts), PH regulators (e.g. citric acid,
Lactic acid, tartaric acid and its salts, diisopropanolamine, etc.: The pH to be adjusted is determined based on the stability of the formulation, and the formulation is usually preferably kept weakly acidic to weakly alkaline. ) etc. can be blended. If necessary, antibiotics (e.g., gentamicin sulfate, fradiomycin sulfate, etc.)
Antihistamines (e.g., diphenhydramine, isothipendyl hydrochloride, etc.), fungicides (e.g., dequalinium chloride, chlorhexidine hydrochloride, etc.)
chlorhexidine gluconate, sulfisomidine), anti-inflammatory agents (e.g. glycyrrhetinic acid,
medicinal ingredients such as indomethacin, dexamethasone acetate, fluocinolone acetonide, betamethasone valerate, hydrocortisone propionate butyrate), vitamin acids (e.g. vitamin A, vitamin D, vitamin E, etc.) and fragrances (e.g.
lavender, neroli, strawberry, heliotrope, rose, amyl acetate, etc.) can be blended in appropriate combinations. Furthermore, if necessary, add a small amount of nonionic surfactant that is less irritating to the skin (for example, fatty acid monoglycerides, sorbitan fatty acid esters, polyoxyethylene higher fatty acid esters, etc.) to the extent that it does not reduce the effectiveness of urea. be able to. The external preparation of the present invention can be produced, for example, by the method described below. That is, a hydrogenated phospholipid is dissolved in a heated fat or oil component, a heated aqueous urea solution is added thereto, and the mixture is cooled while stirring, or all components are mixed together, heated and stirred, and then cooled. Although there are no particular precautions to be taken during production, a preparation for external use with high storage stability can be obtained by making the emulsion particles finer using a homomixer or the like during stirring during heating. (Effect) Preparations containing phospholipids may sometimes cause problems such as discoloration when stored for a long period of time. However, by using a hydrogenated phospholipid, especially a hydrogenated phospholipid with an iodine value of 15 or less, as a dispersant, the external preparation of the present invention does not cause discoloration of the preparation during storage even without using an antioxidant. First, the therapeutic effect on skin dyskeratosis is significantly greater than that of a urea-containing external preparation that uses a synthetic surfactant as a dispersant. Hereinafter, the effects of the external preparation of the present invention will be illustrated by giving test examples. Test Example 1 Various creamy samples were prepared according to Example 1 described below using 10% by weight of soybean phospholipids or hydrogenated soybean phospholipids having different iodine values. 50g of each sample was placed in a transparent glass bottle with a content of 60g and stored in a constant temperature room at 40°C to examine changes over time. The results are shown in Table 1.

【表】 △：僅かに変色する
×：著しく変色する
試験例 ２ 後記実施例１に準じて第２表に示す処方の試料
１〜３を調製した。 中程度の症状を示す進行性指掌角皮症の主婦
（23〜35才）10名を１群として３群を用意し、毎
日水仕事および就寝前に前記各試料をそれぞれ別
個の群の主婦の患部に適量塗布し、１週間後およ
び２週間後の症状の改善度を調べ、それを該当人
数で表わした。 その結果を第３表に示す。[Table] △: Slight discoloration ×: Significant discoloration Test Example 2 Samples 1 to 3 of the formulations shown in Table 2 were prepared according to Example 1 described later. Three groups were prepared, each consisting of 10 housewives (23-35 years old) with progressive digital palmar keratoderma exhibiting moderate symptoms, and each sample was administered to separate groups of housewives each day before washing and before going to bed. An appropriate amount was applied to the affected area, and the degree of improvement in symptoms was examined one week and two weeks later, and the results were expressed in terms of the number of people affected. The results are shown in Table 3.

【表】【table】

【表】 （発明の効果） 本発明の外用製剤は、皮膚角化異常症に対する
治療効果が高く、抗酸化剤を使用することなしに
保存中の製剤の変色、変質を避けることができ、
医薬として利用するができる。 （実施例） 以下、実施例を挙げて本発明を具体的に説明す
る。 実施例 １ 水素添加大豆リン脂質100ｇを流動パラフイン
300ｇに加温溶解し、これにパラオキシ安息香酸
エチル２ｇを加えて溶解し、油相液を調製した。 また、尿素100ｇを精製水394.5ｇに溶解し、こ
れに乳酸２ｇ、乳酸ナトリウム１ｇ、エチレンジ
アミンテトラ酢酸エチルジナトリウム0.5ｇを加
えて溶解した後、更にグリセリン100ｇを加えて
加温、溶解して水相液を調製した。 75℃に加温した前記油相液にほぼ同温度に加温
した水相液を加え、ホモミキサーを用い、
5000rpmで20分間撹拌し、その後撹拌しながら室
温まで冷却してクリーム状の外用製剤1000ｇを得
た。 本品を40℃３個月間保存してその状態を調べた
が、変色、異臭は認められなかつた。 実施例 ２ 水素添加卵黄レシチン10ｇ、白色ワセリン10
ｇ、流動パラフイン100ｇ、パラオキシ安息香酸
メチル４ｇを加温、溶解し、油相液を調製した。 また尿素100ｇを精製水773.8ｇに溶解し、これ
にハイビスワコー２ｇを添加して分散させた後、
ジイソプロパノールアミン0.2ｇを添加して水相
液を調製した。 70℃に加温した前記油相液にほぼ同温度に加温
した前記水相液を加え、ホモミキサーを用いて
5000rpmで15分間撹拌し、その後撹拌しながら室
温まで冷却してローシヨン状の外用製剤1000ｇを
得た。 本品を40℃で３個月間保存してその状態を調べ
たが、変色、異臭は認められなかつた。 実施例 ３ 実施例１に準じて、下記処方のクリーム状外用
製剤を調製した。[Table] (Effects of the invention) The external preparation of the present invention has a high therapeutic effect on skin dyskeratosis, and can avoid discoloration and deterioration of the preparation during storage without using antioxidants.
It can be used as a medicine. (Example) Hereinafter, the present invention will be specifically described with reference to Examples. Example 1 100g of hydrogenated soybean phospholipid was added to liquid paraffin.
300 g was heated and dissolved, and 2 g of ethyl paraoxybenzoate was added and dissolved to prepare an oil phase liquid. In addition, 100 g of urea was dissolved in 394.5 g of purified water, 2 g of lactic acid, 1 g of sodium lactate, and 0.5 g of ethyl disodium ethylenediaminetetraacetate were added and dissolved, and then 100 g of glycerin was added, heated, dissolved, and water was added. A phase solution was prepared. The aqueous phase liquid heated to approximately the same temperature is added to the oil phase liquid heated to 75°C, and using a homomixer,
The mixture was stirred at 5000 rpm for 20 minutes, and then cooled to room temperature while stirring to obtain 1000 g of a creamy external preparation. This product was stored at 40°C for 3 months and its condition was examined, but no discoloration or unusual odor was observed. Example 2 Hydrogenated egg yolk lecithin 10g, white petrolatum 10g
g, 100 g of liquid paraffin, and 4 g of methyl p-oxybenzoate were heated and dissolved to prepare an oil phase liquid. In addition, 100 g of urea was dissolved in 773.8 g of purified water, and 2 g of Hibis Wako was added to it to disperse it.
An aqueous phase liquid was prepared by adding 0.2 g of diisopropanolamine. Add the aqueous phase liquid heated to approximately the same temperature to the oil phase liquid heated to 70°C, and mix using a homomixer.
The mixture was stirred at 5,000 rpm for 15 minutes, and then cooled to room temperature while stirring to obtain 1,000 g of a lotion-like external preparation. This product was stored at 40℃ for 3 months and its condition was examined, but no discoloration or unusual odor was observed. Example 3 According to Example 1, a cream-like external preparation having the following formulation was prepared.

【表】 実施例 ４ 実施例１に準じて下記処方のクリーム状外用製
剤を調製した。[Table] Example 4 According to Example 1, a cream-like external preparation with the following formulation was prepared.

【表】 実施例 ５ 実施例１に準じて下記処方のクリーム状外用製
剤を調製した。[Table] Example 5 According to Example 1, a cream-like external preparation with the following formulation was prepared.

【表】 実施例 ６ 実施例１に準じて下記処方の油性軟膏状外用製
剤を調製した。[Table] Example 6 According to Example 1, an oil-based ointment-like external preparation with the following formulation was prepared.

【表】 実施例 ７ 実施例１に準じて下記処方の油性溶液状の外用
製剤を得た。[Table] Example 7 According to Example 1, an oil-based solution for external use having the following formulation was obtained.

【表】【table】

【特許請求の範囲】[Claims]

１ 有効量のギンゴーライド又はギンゴーライド
誘導体及び薬学的に許容し得る担体を含有してな
る血小板活性化因子によつて誘発される病気の治
療用組成物。 ２ ギンゴーライドはギンゴーライドＡ、ギンゴ
ーライドＢ、ギンゴーライドＣ及びギンゴーライ
ドＭからなる群から選ばれる特許請求の範囲第１
項記載の治療用組成物。 ３ ギンゴーライドとしてギンゴーライドＢを10
〜150mgの量で含有する経口用投与に適する形態
の特許請求の範囲第１項記載の治療用組成物。 ４ ギンゴーライドとしてギンゴーライドＢを１
〜20mgの量で含有する静脈内投与に適する形態の
特許請求の範囲第１項記載の治療用組成物。 ５ ギンゴーライドとしてギンゴーライドＢをス
プレー式１用量当り約１mgの量で含有するスプレ
ー吸入用投与に適する形態の特許請求の範囲第１
項記載の治療用組成物。 1. A composition for treating diseases induced by platelet activating factors, comprising an effective amount of ginkgolide or a ginkgolide derivative and a pharmaceutically acceptable carrier. 2. Gingoride is selected from the group consisting of Gingoride A, Gingoride B, Gingoride C, and Gingoride M. Claim 1
Therapeutic compositions described in Section. 3 Gingo Ride B as Gingo Ride 10
A therapeutic composition according to claim 1 in a form suitable for oral administration containing in an amount of 150 mg. 4 Gingo Ride B as Gingo Ride 1
A therapeutic composition according to claim 1 in a form suitable for intravenous administration containing in an amount of ~20 mg. 5 Claim 1 in a form suitable for spray inhalation administration containing Gingolide B as Gingolide in an amount of about 1 mg per spray dose
Therapeutic compositions described in Section.

JP60102165A 1985-05-14 1985-05-14 Pharmaceutical preparation for external use Granted JPS61260016A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60102165A JPS61260016A (en) 1985-05-14 1985-05-14 Pharmaceutical preparation for external use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60102165A JPS61260016A (en) 1985-05-14 1985-05-14 Pharmaceutical preparation for external use

Publications (2)

Publication Number Publication Date
JPS61260016A JPS61260016A (en) 1986-11-18
JPH0529008B2 true JPH0529008B2 (en) 1993-04-28

Family

ID=14320096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60102165A Granted JPS61260016A (en) 1985-05-14 1985-05-14 Pharmaceutical preparation for external use

Country Status (1)

Country Link
JP (1) JPS61260016A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002167328A (en) * 2000-11-29 2002-06-11 Toyo Aerosol Ind Co Ltd Composition and aerosol composition for external skin preparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201708A (en) * 1982-05-18 1983-11-24 Asahi Chem Ind Co Ltd Cosmetic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201708A (en) * 1982-05-18 1983-11-24 Asahi Chem Ind Co Ltd Cosmetic composition

Also Published As

Publication number Publication date
JPS61260016A (en) 1986-11-18

Similar Documents

Publication Publication Date Title
KR100775803B1 (en) Dermal compositions containing coenzyme q as the active ingredient
US20030170194A1 (en) Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid
JP2009184951A (en) External skin care preparation composition
JP2016130224A (en) External composition
JPH07316075A (en) External preparation for skin
JPS6272611A (en) Skin external preparation
JPS6115809A (en) Cell activator
EP1053221B1 (en) Lipid mixtures and their use
JP2018203674A (en) Sebum secretion promoter and external composition
JPH0529008B2 (en)
JPH07258070A (en) Nose cleaning agent
JP3441387B2 (en) Moisturizer, skin cosmetics and bath additives
KR100888752B1 (en) External dermal agent
JPH03120230A (en) Percutaneous absorbefacient of drug active ingredient and percutaneous absorption type pharmaceutical
JPH0529007B2 (en)
JP2017178798A (en) External composition
JPH072631B2 (en) Gel composition
JP2005314434A (en) Use of composition containing one chelating agent for reducing symptoms associated with histamine release in organism
WO1997028806A1 (en) Treatment for hypercholesterolemia
JPH0899877A (en) Dermatological medicine against heavy infection,containing content of fatty acid and fatty acid glyceride
JPH0788294B2 (en) Cosmetics
JP7153429B2 (en) Active oxygen scavenging agent
JPH029808A (en) Drug for maintaining and recovering health of a skin
JPH04305509A (en) External preparation for skin
JP2018203673A (en) Sebum secretion promoter

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term